Duke Genomics Institute Readies Prospective Trial to Test PGx Model for Chemotherapy | GenomeWeb
CHICAGO (GenomeWeb News) — Duke University’s Institute for Genome Sciences and Policy this fall will launch a prospective Phase IIb trial to learn whether a pharmacogenomic-based prognostic model can be used to change the way oncologists treat an early form of non-small cell lung cancer.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.